IP Library › Granted Patent US 10,179,242
Granted Patent B2
US 10,179,242 · App. 12/797,815 · Granted Jan 15, 2019

Tissue oxygenation monitoring in heart failure

Inventors: Can Cinbis (Shoreview, MN); James K. Carney (Brooklyn Park, MN); Jonathan L. Kuhn (Ham Lake, MN); David A. Anderson (Stanchfield, MN)
Assignee: Medtronic, Inc.
A61N1/36557
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,179,242
App. No.
12/797,815
Granted
Jan 15, 2019
Kind
B2
Abstract

A medical device for monitoring delivery of a therapy that includes a therapy delivery module to deliver a therapy, a controller to set a therapy delivery control parameter, an optical sensor to produce a signal corresponding to tissue light attenuation, and a processor configured to compute a tissue oxygenation measurement from the optical sensor signal, wherein the controller, the optical sensor, and the processor operate cooperatively to determine a setting of the therapy delivery control parameter corresponding to a maximum tissue oxygenation.

Claims (60)

1. A medical device comprising:

a therapy delivery module configured to deliver a therapy based on a therapy delivery control parameter;

an optical sensor for sensing a signal of light attenuated by a localized volume of a blood-perfused body tissue;

a processor configured to:

compute a tissue oxygenation measurement of an availability of oxygen at the localized tissue volume from the optical sensor signal during the therapy being delivered based on the therapy delivery control parameter,

detect a decrease in tissue oxygenation by comparing the tissue oxygenation measurement to a threshold; and

determine an adjusted therapy delivery control parameter in response to the decrease in tissue oxygenation tissue oxygenation.

2. The device of claim 1 , wherein the optical sensor comprises a light emitting portion for emitting at least four spaced apart wavelengths and a light detecting portion for producing a signal corresponding to the tissue light attenuation at the at least four spaced apart wavelengths.

3. The device of claim 2 , wherein the processor is configured to compute a second derivative of the tissue light attenuation with respect to wavelength and computes an absolute tissue oxygen saturation using the second derivative.

4. The device of claim 3 , further comprising the processor being configured to compute a total hemoglobin volume fraction using the absolute tissue oxygen saturation.

5. The device of claim 4 , wherein the processor is configured to determine the adjusted therapy delivery control parameter corresponding to one of a maximum tissue oxygen saturation and a maximum total hemoglobin volume fraction.

6. The device of claim 4 , wherein the processor is configured to compute a tissue oxygenation index using the tissue oxygen saturation and the total hemoglobin volume fraction and to determine the adjusted therapy delivery control parameter corresponding to a maximum tissue oxygenation index.

7. The device of claim 1 , wherein the optical sensor is an external sensor emitting light transcutaneously.

8. The device of claim 1 , wherein the optical sensor is an implantable sensor.

9. The device of claim 8 , further comprising a sealed housing, wherein the optical sensor is configured within the sealed housing.

10. The device of claim 8 , further comprising an electrical lead electrically coupled to the medical device, the lead comprising an elongated lead body, wherein the optical sensor is positioned along the elongated lead body.

11. The device of claim 8 , further comprising a medical device telemetry module, wherein the optical sensor comprises:

a sealed housing; and

a sensor telemetry module configured for bidirectional communication with the medical device telemetry module.

12. The device of claim 1 , wherein the optical sensor comprises a light detecting portion and a light emitting portion, one of the light detecting portion and the light emitting portion being an implantable portion and the other of the light detecting portion and the light emitting portion being an external portion positioned in facing opposition with the implantable portion.

13. The device of claim 12 , wherein the control parameter comprises one of an electrode location, a timing parameter and an electrode selection parameter.

14. The device of claim 1 , further comprising:

a plurality of electrodes for stimulating at least one heart chamber;

a pulse generator configured to deliver pacing pulses to the at least one heart chamber via the plurality of electrodes, wherein the control parameter corresponds to a parameter for controlling cardiac resynchronization therapy.

15. The device of claim 1 , wherein the therapy delivery module comprises:

a catheter; and

a fluid delivery module.

16. The device of claim 1 , wherein the therapy delivery module comprises:

a plurality of electrodes; and

a pulse generator configured to deliver stimulation pulses to a nerve via the plurality of electrodes.

17. The device of claim 1 , wherein the medical device comprises a cardiac assist device for delivering the therapy.

18. The device of claim 1 , further comprising a memory configured to store tissue oxygenation measurements determined by the processor,

wherein the processor is configured to detect the decrease in tissue oxygenation by comparing the tissue oxygenation measurement to a previously determined tissue oxygenation measurement stored in the memory as one of an initial baseline tissue oxygenation measurement or a running average tissue oxygenation measurement.

19. The device of claim 1 , wherein the processor is configured to determine the adjusted therapy delivery control parameter by determining a duty cycle of the therapy that maintains the tissue oxygenation at a stable level.

20. The device of claim 1 , wherein the therapy delivery module is configured to deliver cardiac resynchronization therapy and the processor is configured to determine the adjusted therapy delivery control parameter by determining a duty cycle of the cardiac resynchronization therapy.

21. The device of claim 1 , wherein the processor is configured to determine the adjusted therapy delivery control parameter by determining a duty cycle of a blood pump.

22. The device of claim 1 , wherein the processor is configured to:

detect an increase in the tissue oxygenation; and

determine the adjusted therapy delivery control parameter to reduce therapy delivery in response to detecting the increase in the tissue oxygenation.

23. The device of claim 1 , wherein the processor is configured to determine the adjusted therapy delivery control parameter to maximize the tissue oxygenation measurement when a heart rate is within a predefined heart rate range.

24. The device of claim 1 , further comprising a sensor configured to sense a cardiac electrical signal,

wherein the processor is configured to determine a resting heart rate of a patient from the sensed cardiac electrical signal, and

wherein the processor is further configured to determine the adjusted therapy delivery control parameter to lower the resting heart rate and maintain the tissue oxygenation within a predetermined range.

25. A method for monitoring delivery of a therapy in a medical device, comprising;

delivering a therapy based on a therapy delivery control parameter;

sensing an optical sensor signal of light attenuated by a localized volume of blood-perfused body tissue;

computing a tissue oxygenation measurement of an availability of oxygen at the localized tissue volume from the optical sensor signal during the therapy being delivered based on the therapy delivery control parameter;

detecting a decrease in tissue oxygenation by comparing the tissue oxygenation measurement to a threshold; and

determining an adjusted therapy delivery control parameter in response to the decrease in tissue oxygenation tissue oxygenation.

26. The method of claim 25 , wherein delivering the therapy comprises delivering pacing pulses to at least one heart chamber.

27. The method of claim 26 , wherein the control parameter comprises one of an electrode location, a timing parameter and an electrode selection parameter.

28. The method of claim 25 , wherein delivering the therapy comprises delivering a heart failure medication.

29. The method of claim 25 , wherein delivering the therapy comprises delivering stimulation pulses to a nerve.

30. The method of claim 25 , wherein delivering the therapy comprises delivering a cardiac assist therapy.

31. A non-transitory computer readable medium having computer executable instructions stored thereon that, when executed, cause a medical device:

deliver a therapy based on a therapy delivery control parameter;

sense an optical sensor signal of light attenuated by a localized volume of blood-perfused body tissue;

compute a tissue oxygenation measurement of an availability of oxygen at the localized tissue volume from the optical sensor signal during the therapy being delivered based on the therapy delivery control parameter;

detect a decrease in tissue oxygenation by comparing the tissue oxygenation measurement to a threshold; and

determine an adjusted therapy delivery control parameter in response to the decrease in tissue oxygenation tissue oxygenation.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 19, 2010
From: CINBIS, CAN; CARNEY, JAMES K.; KUHN, JONATHAN L.; ANDERSON, DAVID A.
To: MEDTRONIC, INC.
Reel/Frame 024857/0915 →
Continuity (2)
Provisional Application 61185812 · Jun 10, 2009
Related Publication 20100318146A1 · Dec 16, 2010
Cited By (1)
US 12,656,523